Meropenem Injection IP 1g Seized Worth Rs 5.88 Lakhs For DPCO Violations

Mancherial: Today, Under the supervision of M. SrinivasuIu, AD, Karimnagar I, T.Chandana Drugs Inspector, Mancherial,  seized 118×1 gm vials of Asmero 1gm*(Meropenem Injection IP 1g) B.No: CI22159H, M/d: 09/2022,  E/D:  08/2024, Mfd. by: Curehealth pharmaceuticals Pvt Ltd, Vill. Raipur, P.O. Deothi, Tehsil & Dist. Solan, H.P and  Marketed by: Astam Healthcare Pvt Ltd, Vill. Theda, Teh. Nalagarh, Dist. Solan, H.P for the violation of  Para 13, 14(1) & (2) & 24 of DPCO 2013 r/w 1579(E) dated 31.03.2023.

Prices of 27 formulations were revised vide SO 1579(E) dtd 31.3.2023 with respect to WPI @12.1218%. Ceiling Price of Meropenem Injection IP 1g was originally fixed under NLEM, 2022. Ceiling price of this formulation is revised including WPI : Rs 952.68  for 1g vial on 31.3.2023.

Asmero1gm 1 is found printed with MRP on the label: Rs. 4200/- for 1g vial.

Ceiling price + GST(12%) is worked out to be  Rs 1067 per 1g vial.

As per DCOs, the formulation is printed with Excess : Rs. 3133/- per 1g vial.

Therefore, 1g vial is charged excess of  Rs 3133/- i.e., 293 % Excess MRP.  Total Worth of seized formulation is Rs.5,88,000/-

Related Posts

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

New Delhi: In a major crackdown on the sale of expired and substandard products, the Central Range team of Delhi Police Crime Branch has arrested one person and seized nearly…

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

Washington:  On March 18, 2026, the U.S. Food and Drug Administration (FDA) issued a draft guidance titled General Considerations for the Use of New Approach Methodologies in Drug Development. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

IPC releases draft NFI-2026 to promote rational use of medicines

IPC releases draft NFI-2026 to promote rational use of medicines

Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

US market to dent India pharma earnings even as domestic growth remains firm

US market to dent India pharma earnings even as domestic growth remains firm

Biocon Pharma receives USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg

Biocon Pharma receives USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg